Viedma

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma2 trials
• Head and neck cancer1 trial
• Lung cancer1 trial
• Ovarian cancer1 trial

Phase

• Phase 33 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Recruiting4 trials
• Active, not recruiting1 trial

Lead sponsor

• GlaxoSmithKline5 trials

Running trials

• Recruiting

  Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]

  NCT07694427· Phase 3· GlaxoSmithKline· Source

  Contact: Rubén Kowalyszyn (principal investigator)

• Recruiting

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101· Phase 3· GlaxoSmithKline· Source

  Contact: Rubén Kowalyszyn (principal investigator)

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

  Contact: Rubén Kowalyszyn (principal investigator)

• Recruiting

  A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

  NCT05714839· Phase 1/2· GlaxoSmithKline· Source

  Contact: Rubén Kowalyszyn (principal investigator)

• Active, not recruiting

  Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

  NCT04655976· Phase 2/3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma2 recruiting
• Head and neck cancer1 recruiting
• Ovarian cancer1 recruiting